Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient d

Trial Details

NCT ID
NCT05842174
Phase
PHASE1 / PHASE2
Sponsor
VA Office of Research and Development
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Hydroxychloroquine
  • Lipiodol
  • Placebo
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE
  • HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified,…
  • Childs Pugh Turcotte A/B7, Performance Status 0
  • Informed of investigational nature of this study with provision of signed and dated informed consent form

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →